CCT: Impact of Intensive Computerized Cognitive Training

Sponsor
Brigham and Women's Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06130735
Collaborator
Fujifilm (Industry)
30
1
1
12
2.5

Study Details

Study Description

Brief Summary

To investigate factors that predict cognitive enhancement following engagement in an intensive Computerized Cognitive Training Protocol.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Computerized Training
N/A

Detailed Description

To investigate factors that predict cognitive enhancement following engagement in an intensive 6-month, 5 days per week training use the ABI Wellness BEARS platform and Brainex Software Symbol Relations Module.

The study will examine the impact of intensive working memory training on neurocognitive markers of brain plasticity (intervention-related changes) in 1) performance on neuropsychological tests, 2) BDNF levels in blood and salivary, 3) ERP measures of working memory, and 4) resting state fMRI and structural MRI.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Clinical trials with a single arm.Clinical trials with a single arm.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Computerized Cognitive Training: Characterization of Factors That Predict Cognitive Enhancement in Acquired Brain Injury
Actual Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Computerized Cognitive Training

See section of intervention/treatment for additional information.

Behavioral: Cognitive Computerized Training
Participants will log into ABI Wellness Platform five days per week (M-T-W-Th-F) and train using the Symbol Relations module for 45 to 60 minutes. Every other week, participants will meet with their training facilitator via zoom to review training progress and troubleshoot any training-related questions.

Outcome Measures

Primary Outcome Measures

  1. Changes in cognitive outcome measures [6 months]

    We will use age-corrected standard scores of the NIH toolbox Total Cognitive Composite, Fluid Intelligence Composite, and individual scores on RAVLT, Verbal Fluency, and Trailmaking Task as cognitive outcome measures.

  2. Changes in BDNF Levels in blood and saliva [6 months]

    Using FUJIFILM high sensitivity ELISA kits and commercially available ELISA kits.

Secondary Outcome Measures

  1. Self-report exercise and physical activity [6 months]

    Physical Activity Scale for the Elderly (questionnaire). Measures walking, moderate, and vigorous activity. Zero lower limit, no upper limit. Higher values indicate more physical activity.

  2. Intervention-related changes in ERP measures, such as the P3 component (P3a and P3b) [6 months]

    1) Measured in response to verbal and visual working memory tasks

  3. Intervention-related changes in resting state fMRI [6 months]

    A group ICA analysis procedure will be applied to pre- and post-intervention rs-fMRI BOLD signal activity. Correlations will be explored between fMRI parameters, cognitive, and training data (e.g NIH toolbox Total Cognitive Composite, Fluid Intelligence Composite, Crystallized Composite, CCT engagement and progress).

  4. Quality of life self-report [6 months]

    Flanagan Quality of Life Scale (questionnaire). Measures quality of life. Likert scale 0-112, higher values indicate higher quality of life.

  5. Sleep [6 months]

    Medical Outcomes Study Sleep Scale (questionnaire) Likert scale measuring sleep quality and sleep problems index. 0-60 with greater values representing higher sleep quality and lower sleep problems.

  6. Anxiety [6 months]

    Generalized Anxiety Disorder 7 Item Scale (questionnaire) Likert scale measuring severity of anxiety. 0-21 with greater values representing more severe anxiety.

  7. Depression [6 months]

    Patient Health Questionnaire Depression Scale (questionnaire) Likert scale measuring the severity of depression. 0-24 with higher scores representing more severe depression.

  8. Self-report on impact of fatigue [6 months]

    Modified Fatigue Impact Scale Likert scale on the impact of fatigue on one's physical, cognitive, and psychosocial activity. 0-84 with higher scores indicating a greater impact of fatigue on a person's activities.

  9. Feelings about cognitive/thinking skills [6 months]

    Cognitive Self- Efficacy Questionnaire Likert scale on feelings people have about their cognition/thinking skills. 0-72 with a higher score indicating more positive feelings regarding the efficacy of ones cognitive/thinking abilities.

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient of the Mass General Brigham Health System with primary attention and executive functioning difficulties and/or a diagnosis of mild cognitive disorder or mild neurocognitive disorder (non-amnestic profile), due to an acquired brain injury (ABI) sustained at least 12 months prior to study contact.

  • Ages 25-65 years old

  • Proficiency in English

  • Willing and able to complete all study-related activities for 12 months, including travel to Brigham and Women's Hospital (Boston) for four in-person assessment visits and two serum and saliva sample collections.

  • Access to a computer with webcam and stable internet.

  • A reliable study informant who can complete one questionnaire about participant's cognition/daily functioning, at four time points.

Exclusion Criteria:
  • History of alcohol or substance abuse, or dependence, within the past 2 years, as per DSM-5 criteria.

  • High likelihood of an underlying progressive neurodegenerative disorder.

  • Evidence of moderate to severe cognitive disorder, based on a score of 21 or less on the Mini-Mental Status Examination (MMSE) (Tombaugh & McIntyre, 1992).

  • Patient Health Questionnaire (PHQ)-9 (Kroenke et al., 2010) Score ≥ 19, unless deemed by treating provider not to have active depression (e.g., adjustment disorder, grief reaction).

  • Active psychotic symptoms.

  • Severe sensory losses such that participants would unlikely be able to participate in the study training, even with substantial accommodations (self-report of extreme difficulty reading ordinary newspaper print or a performance-tested corrected vision test score of worse than 20/30).

  • Communication difficulties that prevent the participant from effectively participating in this highly interactive study protocol (based on interviewer's rating of a person's ability to be understood and to understand others).

  • Current participation in a pharmacological, or other interventional research trial.

  • Life expectancy of < 2 years.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brigham and Women's Hospital Boston Massachusetts United States 02115

Sponsors and Collaborators

  • Brigham and Women's Hospital
  • Fujifilm

Investigators

  • Principal Investigator: Kim C Willment, PhD, Brigham and Women's Hospital
  • Principal Investigator: Kirk R Daffner, MD, Brigham and Women's Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Kirk Daffner, MD, Chief, Division of Cognitive and Behavioral Neurology, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT06130735
Other Study ID Numbers:
  • 2022P003401
First Posted:
Nov 14, 2023
Last Update Posted:
Nov 14, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kirk Daffner, MD, Chief, Division of Cognitive and Behavioral Neurology, Brigham and Women's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 14, 2023